Abstract Opioids are among the most effective analgesics in controlling the perception of intense pain, although their continuous use decreases their potency due to the development of tolerance. The glutamate N-methyl-D-aspartate (NMDA) receptor system is currently considered to be the most relevant functional antagonist of morphine analgesia. In the postsynapse of different brain regions the C terminus of the mu-opioid receptor (MOR) associates with NR1 subunits of NMDARs, as well as with a series of signaling proteins, such as neural nitric oxide synthase (nNOS)/nitric oxide (NO), protein kinase C (PKC), calcium and calmodulin-dependent kinase II (CaMKII) and the mitogen-activated protein kinases (MAPKs). NO is implicated in redox signaling and PKC falls under the regulation of zinc metabolism, suggesting that these signaling elements might participate in the regulation of MOR activity by the NMDAR. In this review, we discuss the influence of redox signaling in the mechanisms whose plasticity triggers opioid tolerance. Thus, the MOR C terminus assembles a series of signaling proteins around the homodimeric histidine triad nucleotide-binding protein 1 (HINT1). The NMDAR NR1 subunit and the regulator of G protein signaling RGSZ2 bind HINT1 in a zinc-independent manner, with RGSZ2 associating with nNOS and regulating MOR-induced production of NO. This NO acts on the RGSZ2 zinc finger, providing the zinc ions that are required for PKC/Raf-1 cysteine-rich domains to simultaneously bind to the histidines present in the HINT1 homodimer. The MOR-induced activation of phospholipase β (PLCβ) regulates PKC, which increases the reactive oxygen species (ROS) by acting on NOX/NADPH, consolidating the long-term PKC activation required to regulate the Raf-1/MAPK cascade and enhancing NMDAR function. Thus, RGSZ2 serves as a Redox Zinc Switch that converts NO signals into Zinc signals, thereby modulating Redox Sensor Proteins like PKCγ and Raf-1. Accordingly, redox-dependent and independent processes weave together to situate the MOR under the negative control of the NMDAR.
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Regulation of the Mu Opioid Receptor Function in the Nervous System
Opioid drugs like morphine are currently amongst the most efficacious pain relievers available, although their clinical use must follow specific protocols in order to delay the progressive loss in their potency that is provoked by repeated administration. Higher drug doses are needed to obtain the expected benefits when opioid tolerance develops, with an increased risk of adverse effects, such as respiratory depression, cognitive changes, or physical and psychological drug dependence. At present, it is thought that tolerance to opioid antinociception initiates as a consequence of the regulatory mechanisms that normally operate to control the strength of the opioid signal. In rodents, morphine tolerance can be observed after just a single adequate dose of the opioid [1, 2] , and long-term administration leads to more profound tolerance and to physical dependence on this substance. However, the tolerance and physical dependence produced by single opioid doses is milder than that induced by chronic morphine administration [3, 4] , suggesting that these are different points of a continuous adaptive process [5] .
Of the main opioid receptors present in the nervous system, the mu-opioid receptor (MOR) is mostly responsible for the potent analgesic effects of morphine and derivatives. Acute doses of opioids trigger a series of adaptive changes that negatively modulate the signaling capacity of the MOR. Thus, if the strength of the MOR signal does not exceed a particular threshold, morphine clearance disrupts these processes and the receptor recovers its full signaling capacity. However, when MOR signaling breaches the aforementioned threshold the receptor undergoes long-term changes that attenuate the potency of successive opioid doses, thereby consolidating acute tolerance. Thus, chronic opioid treatment produces the changes of a single dose and consolidates other alterations, some triggered by the first dose, that require subsequent and repeated receptor activation [6, 7] . Accordingly, distinct mechanisms are likely to be more important at different stages of chronic opioid exposure. As therapeutic use of opioids in humans is limited by the development of analgesic tolerance, particularly for the clinical treatment of chronic pain, pharmacological interventions targeting the most upstream adaptive changes will be beneficial in both acute and chronic treatment regimes.
The MOR is a G protein-coupled receptor (GPCR) that regulates a diverse spectrum of cellular effectors. The classical model of GPCR desensitization implicates agonistinduced receptor phosphorylation by different serine and threonine kinases, followed by its internalization [8, 9] . The efficacy of this control resides in the reduction of functional binding sites, and it is considered the predominant cellular mechanism to attenuate and circumstantially desensitize GPCR signaling [10] . Notwithstanding, morphine induces strong antinociceptive tolerance in the mature nervous system without any significant internalization of MORs. Conversely, agonists like [D-Ala 2 ,N-MePhe 4 , Gly-ol 5 ]-encephalin (DAMGO) that do promote efficient phosphorylation by G protein-coupled receptor kinase 2 (GRK2) and β-arrestin-mediated endocytosis of MORs only produce weak tolerance. This is because most of the DAMGO-internalized MORs recycle back to the membrane and resensitize the cell to the subsequent exposure to the opioid agonist [11, 12] . Given that most of the internalized MORs eludes destruction in the lysosomal compartment and returns to the plasma membrane, endocytosis of this kind of GPCR provokes resensitization rather than desensitization (see references in [6, 13] ). Accordingly, high acute doses of morphine induce strong tolerance because they provoke desensitization of the MORs without promoting their internalization/recycling and resensitization [11] . However, and consistent with the idea of consolidating regulatory mechanisms initiated by acute exposure, some internalization and recycling of tolerant neural MORs does occur during chronic morphine treatment, sufficient to preserve a limited analgesic effect [6] . These observations demonstrate that besides the classical desensitization process, GPCR responses can also be diminished without reducing the number of receptors in the membrane. In neural cells, MOR agonists like morphine and its derivatives are poor inducers of receptor internalization and they recruit other adaptive processes to disrupt MOR regulation on G-proteins [14] [15] [16] [17] [18] . These processes rely on the long-term transfer of MORregulated Gα subunits and Gβγ dimers to the control of specialized proteins [19] [20] [21] [22] [23] [24] [25] [26] .
Research performed by many groups over the past years has provided valuable information on the molecular substrates implicated in the development of opioid nociceptive tolerance. Thus, certain hormonal and neurotransmitter systems have consistently been related to opioid desensitization, and more specifically, the N-methyl-D-aspartate acid glutamate receptor (NMDAR)/neural nitric oxide synthase (nNOS)/calcium (Ca 2+ ) and calmodulin (CaM)-dependent kinase II (CaMKII) pathway is believed to play an essential role in this process. The recent finding that MORs and NMDARs establish direct physical associations in postsynaptic structures has strengthened this idea [7] . Indeed, pharmacological interventions directed towards NMDARs, nNOS, protein kinase C (PKC), protein kinase A (PKA), CaMKII, delta-opioid receptor (DOR) and the proteins that regulate G-protein signaling (RGS) have shown to prevent, regulate or even rescue opioid analgesia from tolerance [see references in 27] .
These observations led us to propose that the elements targeted by the treatments that most effectively diminished morphine tolerance were integrated in a common regulatory pathway. As a result, these signaling components would connect MORs with NMDARs enabling signals originating from the MORs to increase the activity of NMDARs, in turn exerting a negative feedback on MOR signaling. An interesting feature of this regulatory loop is that the activities of MORs and NMDARs interweave and interact with each other to ultimately desensitize the MOR [28] . Moreover, redox mechanisms implicating NO production and the release of zinc ions from endogenous stores are necessary to maintain the cross-regulation between MORs and NMDARs [29] . In the following sections, we describe the fundamental elements of this integrated regulatory pathway, and how redox-dependent and redox-independent processes contribute to the assembly of signaling proteins around the cytosolic C-terminal sequence of the MOR.
Cross-Regulation Between the MOR and NMDAR
Regulation of the MOR in the mature nervous system differs greatly from that observed in cultured cells derived from other tissues or in immature neural cells in which the key signaling proteins influencing the activity of this receptor are expressed poorly. Thus, the expression of NMDAR, PKCγ, nNOS and Gαz subunits, as well as certain RGS proteins like RGSZ1 or RGS9, is virtually restricted to nervous tissue, and most of these proteins only express in mature neural cells when integrated into functional networks. Although we now know that NMDAR activity is essential for the development of morphine analgesic tolerance, it has taken some time to understand how NMDARs influence MOR signaling. The initial evidence suggested a cross-talk between these receptors and later, it was proposed to occur in the same postsynaptic compartment. More recently, it was demonstrated that MORs and NMDARs establish direct physical interactions through their cytosolic sequences [7] . This physical interaction appears to be necessary for their cross-talk, which operates as a regulatory loop between activated MORs and MOR-regulated NMDARs in the absence of significant internalization of the opioid receptor.
Integrated Pathway Components
In this section, we will focus on the signaling proteins implicated in sustaining the MOR-NMDAR regulatory loop. The essential elements of MOR-NMDAR crossregulation are shown in Fig. 1 .
HINT1
The HINT1 protein is a zinc-binding protein that belongs to the histidine triad (HIT) protein family of nucleotidyl hydrolases and phosphotransferases [30, 31] , and that contains the HisXHisXHis sequence (where X is a hydrophobic amino acid) [32] . HINT1 was initially referred to as the PKC-interacting protein (PKCi), as it binds to and inhibits PKC function [33] . HINT1 has tumor suppressor properties [34] , probably related to its repression of β-catenin signaling [35] , and it binds to the C terminus of the MOR [36, 37] , linking this receptor to the N terminus of RGS-Rz proteins RGSZ1 and RGSZ2 [37, 38] . Upon activation of the MOR, this HINT1-RGSZ2 complex recruits other proteins to the MOR environment, such as the inactive form of neuralspecific PKCγ [39] . Data from structural studies, yeast two-hybrid systems and the biochemical purification of HINT1 from bovine brain indicate that HINT1 is a 126 amino acid protein of about 14 kDa that exists as a homodimer [37, 40] . The protomers join through their central and C-terminal sequences forming a negatively charged surface, whereas the N-terminal regions remains separated. The HINT1 C terminus governs its catalytic function [41] and notably, the formation of the homodimer does not require the association of zinc [40] . Therefore, the two set of histidines 110, 112 and 114 plus histidine 51, are exposed in the surface available to bind zinc in their interaction with third party proteins (Fig. 2a) .
In ex vivo studies, we determined that the interaction of HINT1 with the MOR C terminus was resistant to zinc chelation (N,N,N′,N′, tetrakis(2-pyridylmethyl)ethylenediamine: TPEN-EDTA buffer) and neither NO donors nor added zinc enhanced their association [29, 37, 39] . In vitro, after removing zinc from the recombinant MOR C-terminal sequence and the HINT1 protein, exogenous zinc did not increase their association above that observed in the absence of added ions [29] . By contrast, the binding of PKCγ to HINT1 relies on the availability of these metal ions. Notably, in mouse brain synaptosomes NO donors such as (S)-nitroso-Nacetylpenicillamine (SNAP) and (±)(E)-ethyl-2-[(E) hydroxyimino]-5-nitro-3-hexeneamide (NOR-3) fomented the association of PKCγ with HINT1, suggesting the oxidative release of zinc ions from thiol groups in cysteine-rich [29, 39, 42] . This zinc-mediated binding of PKCγ to the HINT1 homodimer stabilizes the kinase in its inactive form at the MOR C terminus, and in this state, the binding of phorbol esters or diacylglycerol to the PKC regulatory domain releases part of its zinc content and sets the kinase free in its active form [29, 39, 43, 44] .
RGSZ2
After binding their extracellular ligands, GPCRs activate heterotrimeric G proteins. G proteins contain Gα, Gβ and Gγ subunits, the Gβ and Gγ forming a stable dimer. To form the effector-inactive heterotrimeric G protein under GPCR regulation, the Gα subunit binds GDP to associate with the Gβγ dimer. The activation of GPCRs promotes the exchange of GTP for GDP in this Gα subunit, causing its dissociation from the GPCR and the Gβγ dimer. The receptor activated GαGTP binds to and regulates cellular effectors, thereby propagating the signals originated at the GPCR. When bound to its effectors, the GαGTPase initiates the conversion of GTP into GDP, and this Gα transition state is then bound rapidly by the RGS proteins that act as GTPase-activating proteins (GAP), accelerating the hydrolysis of GTP to GDP and rapidly terminating GPCR signaling. Therefore, RGS protein do not display avidity for the effector inactive GαGDP form and most RGS subfamilies exhibit weaker affinity for the GPCR-activated GαGTP form than for the GαGTP hydrolysis transition state [45, 46] . Binding of the GPCR-activated GαGTP subunits to their effectors generates this transition state and thus, the subunits can safely reach and regulate the effectors before the binding of RGS proteins promote their deactivation. The potency and duration of the effects initiated by GPCRs depends on the continuous and efficient reconstitution of the pool of receptorregulated heterotrimeric G-protein [14, 15] . It is here that RGS proteins help synchronize the extent of receptor activation with the corresponding regulation of the target effectors.
The members of the RGS-Rz subfamily present in the nervous system, RGS17 (Z2) and RGS20 (Z1) are proteins of a moderate size, containing 210 and 239 amino acids, respectively. RGSZ2 contains a RGS box or RH domain, a conserved region comprised of nine alpha helices that binds to the receptor activated Gα subunits (residues . The RH domain is flanked by a short C terminus of 12 amino acids and a CDR at its amino-terminus (residues 28-45). The protein also contains several putative casein kinase 2 and PKC phosphorylation sites, a series of PDZ domain binding motifs (61-64 MESI, 75-78 ADEV and 76-79 DEVL), a covalent binding site for Small Ubiquitin-like MOdifier (SUMO) in the RH domain (K121 in LKKE), and SUMO-interacting motifs (SIMs), one upstream of the RH (IQVL: 64-67) and a second within this region (ISIL: 141-144) [29, [47] [48] [49] [50] (Fig. 2b) . The different sizes of these proteins are mostly due to the attachment of SUMO chains at the RH domain, a post-translational modification that abolishes the GAP activity of RGSZ2 and that converts this protein into a scaffold for these subunits during their interaction with third party signaling proteins [48, 50] . The RGSZ-Rz proteins are functionally linked to the MOR [23, 26, 50] , and the HINT1 homodimer couples the N terminus of RGSZ1 and RGSZ2 proteins to the MOR C terminus [37, 38] . Using a series of ex vivo and in vitro approaches, we determined that HINT1-RGSZ2 binding was zincindependent and therefore, that it does not influence the possible function of the RGSZ2 CRD [29, 37] .
Notably, the RGS-Rz subfamily differs from other RGS proteins in that its members exhibit comparable avidity for both GαGTP and the transition state [51] . As this characteristic is observed for effectors, we explored whether RGSZ2 might fulfill such an effector role, and MOR-activated GαGTP subunits did appear to regulate the physical interaction between RGSZ2 proteins and third partner proteins, mostly nNOS [49] . nNOS There are currently three major isoforms of nitric oxide synthases: neuronal (nNOS or NOS-1), inducible (iNOS or NOS-2) and endothelial (eNOS or NOS-3). The predominant source of NO in neurons is due to the activity of nNOS, which is located in synaptic spines. In addition, nNOS is also present in skeletal muscle, cardiac muscle and smooth muscle [52] [53] [54] [55] , where NO controls blood flow and muscle contractility [56] [57] [58] . Neuronal NOS is 1,434 amino acid protein with a predicted molecular weight of 161 kDa [59] and it is active as a homodimer that requires tetrahydrobiopterin (BH4), heme and L-arginine binding [60] . The monomer contains a regulatory Ca 2+ -CaM binding motif flanked by a bidomain structure that contains an oxygenase domain (N-terminal) and a reductase domain (C-terminal). The oxygenase domain that binds the substrate L-arginine contains a tetrahydrobiopterin (BH4) binding site and a cytochrome P-450-type heme active site, as well as a binding site for zinc that facilitates nNOS dimerization. The reductase domain binds the NADPH substrate and it contains a binding site for FMN, FAD [61] [62] [63] -CaM binding [64] . Overall, nNOS catalyzes the oxidation of L-arginine to generate citrulline and NO as products in a wide range of tissues.
The N terminus of nNOS contains a PDZ domain that can interact with PDZ binding motifs. Such a PDZ binding motif is present in the RGSZ2 N-terminal sequence, after the CRD and upstream of the RH domain [49] . Indeed, RGSZ2 coprecipitated nNOS from mouse brain synaptosomes and the recombinant RGSZ2 N-terminal sequence binds to the nNOS PDZ domain (Fig. 3) . Other experimental approaches confirmed their direct physical interaction, such as in vivo bimolecular fluorescence complementation (BiFC) and in vitro surface plasmon resonance (SPR), and in vitro studies demonstrated that RGSZ2 binding to nNOS antagonizes the production of NO [49] . Consistent with this observation, MOR-associated nNOS lacks Akt-activating phosphorylation, probably due to the inhibition exerted by RGSZ2 [49, 65] . In this compartment, morphine promotes the activation of MOR-regulated G proteins and then activates the PI3K/AKT/nNOS pathway. The freed Gβγ dimers contribute to PI3K/Akt activation, whereas GαGTP subunits bind RGSZ2 and release nNOS from its inhibition. This process is accompanied by the separation of Gα.RGSZ2-nNOS from the MOR environment and the activation of NO production by Akt. Accordingly, the experimental removal of nNOS inhibition (e.g., mice with limited RGSZ2 content) facilitates Ca 2+ -CaM/Akt-mediated NO production. Thus, via PI3K/Akt morphine now induces the rapid over-activation of nNOS/NO pathways, promoting strong and long-lasting analgesic tolerance [49] .
In the absence of the HINT1 protein that links the RGSZ2 with the MOR, the RGSZ2-nNOS inhibitory complex exists separated from the MOR, and in these circumstances RGSZ2 hardly binds to the morphine-activated Gα subunits. Consequently nNOS remains inhibited and the MOR-associated NMDAR/CaMKII pathway is not activated [37] . Thus, the association of RGSZ2-nNOS with the HINT1 protein at the MOR C terminus is essential for Fig. 3 The essential protein assembly at MOR C terminus. Diagram showing diverse signaling proteins assembled at the MOR C terminus. Homodimeric HINT1 binds to the MOR C terminus, covering the TSST amino acid sequence critical for GRK2 phosphorylation [37] . RGS-Rz proteins, like RGSZ1 and RGSZ2, bind to the HINT1 homodimer via their N-terminal sequence [37, 38] . In addition, the PDZ domain in the N terminus of neural nNOS couples to the PDZ binding motifs in an internal region of RGSZ2 [49] . HINT1 is a zinc binding protein [40] , and RGSZ2 carries a CRD that can bind to and release zinc ions under redox regulation [29] NMDAR to negatively regulate MORs when triggered by morphine.
PKC
The MOR is known to potentiate NMDAR-mediated glutamate responses by activating PKC [66] . In general, GPCRs regulate the activity of NMDARs via non-receptor tyrosine kinases (NRTKs), like Src and Fyn, and serine and threonine kinases such as PKC [67] . In this pathway PKC acts upstream of Src to regulate the Ca 2+ currents produced by MOR-associated NMDARs. Src phosphorylates specific residues in the cytosolic tails of the NMDAR NR2A and NR2B subunits [68, 69] , which increases the permeation of Ca 2+ ions to the cytosolic side of the postsynaptic membrane. This enhances the activation of CaMKII, which in turn negatively regulates MOR signaling.
The Src family of kinases interacts directly with specific proteins that influence their behavior and while some of these interactions are inhibitory, other disrupt the inhibitory intramolecular interactions, displacing SH2 or SH3 domains and thereby promoting their activation [68, 69] . Indeed, whereas small GTPases such as H-Ras bind to and inhibit Src function, Gαi exerts a positive effect on Src [70, 71] . The neural specific Gz protein behaves as a pTyr527-independent inactivating chaperone for Src, stabilizing the kinase in its inactive form. The binding of morphine to the MOR recruits inactive PKCγ to the HINT1 protein in a NO and zinc-dependent manner, until the action of MOR-freed Gβγ dimers on phospholipase β (PLCβ) augments the DAG and free Ca 2+ , separating PKC from HINT1 and activating the kinase. As a result, PKC disrupts the Gαz-Src complex and this NRTK can therefore bind to GαiGTP subunits and undergoes activating autophosphorylation at Tyr416. PKCγ is a redox sensor that reduces the competition between Gαz and Gαi2 for the control of Src, facilitating the transfer of Src from GαzGDP to Gαi2GTP subunits, where it becomes activated to increase the activity of the NMDAR by acting on NR2 subunits [72] .
Activated PKCγ also directly increases the efficiency of NMDAR signaling. The open probability of NMDAR channel is greatly reduced by binding of the Ca 2+ -CaM complex to the C1 region of NR1 subunits. PKCγ phosphorylates serine residues in this NR1 region, preventing this inhibitory binding and increasing the open probability of the channel [73] . Therefore, the positive effect of PKCγ on the NMDAR is mediated by activation of Src and also by PKCγ acting directly on NR1 subunits.
Raf-1
PKC shares its structure with other serine/threonine kinases such as Raf (Fig. 4) . Both are linear kinases with an Nterminal regulatory domain and a C-terminal catalytic domain, and they also contain zinc-binding CRDs in their respective regulatory domains. Thus, NO-released endogenous zinc ions also recruit the Ras/Raf-1/ERK1/2 cassette to the HINT1 protein. A-Raf and B-Raf associate poorly or not at all with the MOR and as seen for conventional PKCs, zinc ions bridge the association of the Raf-1 CRD with HINT1 at the MOR C terminus. Morphine simultaneously recruits the inactive forms of PKCγ and Raf-1 via NO/zinc to the MOR-HINT1 complex and since activation of MORs activates PKCγ, this association will enhance Raf-1 function and intensify MEK/ERK1/2 activation. Thus, the MOR-HINT1 complex facilitates the cross-talk of two redoxand zinc-regulated signal transduction pathways, PKC/Src and Raf-1/ERK1/2, implicated in the potentiation of NMDAR function and consequently, in the negative control of opioids' effects [39, 42] .
NMDAR NR1 Subunit
Anatomical studies have shown that MORs and NMDARs co-localize in many regions and individual neurons in the nervous system [revised in 74], as well as at the ultrastructural level [75] . The midbrain periaqueductal grey (PAG) is densely innervated by glutamatergic projections from the forebrain, and there is robust MOR-NMDAR colocalization in the dendrites and somata of ventrolateral PAG neurons [76, 77] , a mesencephalic region that is implicated in the opioid control of nociception. Therefore, Fig. 4 The primary structure of Raf-1 and of the conventional PKCs (α, β, γ). Raf-1: C1-C3 conserved regions; the N-terminal regulatory region contains C1 and C2; the C1 region is comprised of the Rasbinding domain (RBD) and the cysteine-rich domain (CRD); the Cterminal C3 region corresponds to the catalytic domain. PKC: C1-C4 conserved regions; the N terminus contains the regulatory region with the pseudo-substrate (PS); C1 is comprised of tandem C1A and C1B cysteine-rich domains (CRDs) that bind zinc and phorbol esters/diacylglycerol; C2 binds phosphatidylserine and calcium; the C-terminal region contains the ATP-binding site (C3) and the kinase domain (C4) that binds the substrate. In both kinases, the N-terminal regulatory domain regulates (inhibits) the activity of the C-terminal catalytic domain (taken from [39, 42]) there is convincing evidence that the MOR and NMDAR coexist at certain postsynaptic sites, and that both receptors show an electrophysiological interaction in individual neurons, which is likely to be responsible for MOR-NMDAR cross-regulation without ruling out a direct interaction between them [7] .
The NMDAR constitutes a cationic channel that is highly permeable to Ca 2+ , and it is formed by a tetramer consisting of a pair of NR1 subunits that associate with at least one type of NR2 (A, B, C, and D) or NR3 (A and B) subunit [78] . There is certain variability in the distal C terminus of NR1 subunits and they are classified as C2 and C2′ [79] . The C terminus of the NR1 subunit is composed of C0-C1-C2(C2′) regions; however, some NR1 lack the C1 segment, C0-C2(C2′). A series of ex vivo and in vitro studies indicate that NR1 subunits containing the C1 regulatory segment in its C-terminal sequence bind to the MOR C terminus, and that the HINT1 protein could stabilize this interaction [7] (Fig. 5) . Morphine disrupts this complex by PKC-mediated phosphorylation of the NR1 C1 segment which protects from Ca 2+ -CaM inhibitory binding and potentiates the NMDAR-CaMKII pathway that is implicated in morphine tolerance. Inhibition of PKC, but not PKA or G-protein receptor kinase 2 (GRK2), restores the MOR-NR1 association and also rescues the analgesic effect of morphine as well. The intracerebroventricular administration of NMDA promotes the separation of the MOR-NR1 complexes, increases MOR serine phosphorylation, reduces the association of the MOR with G proteins, and diminishes the antinociceptive capacity of morphine. Inhibition of PKA, but not PKC, CaMKII or GRK2, blocks the effects of NMDAR activation and preserves morphine antinociception.
Nitric Oxide and Zinc-Mediated Protein Assemblies Associated with the Regulation of the MOR Function by the NMDAR

Essential Components of MOR-NMDAR Connection
As mentioned above, the cross-talk between the MOR and NMDAR is materialized through the precise regulation of a series of signaling proteins that functionally and physically connect both receptors. Components of this protein complex assemble and disassemble in response to the appropriate signals emanating from the MOR and NMDAR. The essential machinery consists of the MOR itself, the regulated G proteins, the HINT1 homodimer at MOR C terminus that binds RGSZ2-nNOS, the C1 segment of NR1 subunits, PKC and Raf-1, as well as the NRTK Src and CaMKII. In this scenario, morphine stimulates the production of NO via RGSZ2-regulated nNOS and the subsequent release of zinc ions from endogenous stores [39, 42, 49] . In mice with limited RGSZ2 protein, morphine does not cause the release of zinc ions from mouse brain slices, which suggests the source of zinc ions is proximal, particularly considering the exquisite compartmentalization of nNOS activity in the MOR environment [29] . Indeed, the CRD located at RGSZ2 N terminus binds two equivalents of zinc which can be released by NO donors and strong oxidants, but not by phorbol esters. Therefore, the RGSZ2 zinc-finger may be regulated by mild nNOS/NO oxidation to supply PKC with the zinc ions necessary for each activation cycle. When coupled with the reversibility of zinc binding upon reduction of the oxidized sulfur, this property makes cysteinecoordinated zinc fingers highly efficient redox sensors [80] . Thus, the RGSZ2 protein emerges as a potential redox zinc switch that converts NO signals into zinc signals that can modulate the function of redox sensor proteins like PKCγ or Raf-1.
Zinc Ions and Redox Mechanisms
Through their binding to thousands of proteins, zinc ions are critical for cell proliferation, differentiation, signaling, and The MOR is a GPCR that couples to G proteins, mainly via its second and third internal loops. In certain postsynaptic structures, the Cterminal sequence of MOR interacts directly with the C1 segment of the NMDAR NR1 subunit [7] . When associated with the MOR, the HINT1 protein participates in the interaction with the NR1 C1 that inhibits NMDAR function survival [81] . Therefore, intracellular zinc concentration is strictly controlled by zinc importers, exporters, and binding proteins such as metallothioneins. This metal element is found in a variety of body tissues at concentrations clearly superior to those of trace elements, including skin, bone, liver, muscle and brain, closing to the levels of energy molecules such as ATP. Indeed, zinc is particularly abundant in the mammalian brain, with concentrations in the μM range, yet the resting concentrations of free cytosolic zinc ions remain in the picomolar to low nanomolar range. While these resting levels of zinc can regulate the activity of certain proteins [82] , the propagation of cellular signals requires substantial oscillations in free zinc levels such those occurring for intracellular calcium. Therefore, low-affinity zinc-binding signaling proteins would be transiently and safely regulated by spatially restricted increases in the concentrations of free zinc ions that will be immediately buffered to the aforementioned resting levels [83] . This tight regulation allows zinc ions to participate in redox-mediated cell signaling. Accordingly, de-regulation of zinc metabolism is associated with neurological diseases including Alzheimer's disease, amyotrophic lateral sclerosis, depression, epilepsy, ischemia, and schizophrenia [84] .
In neural tissue nNOs is primarily responsible for the production of NO, which regulates a broad range of physiological functions. NO can react with Zn/S sites of cysteine clusters in zinc finger proteins, resulting in S-nitrosylation and the release of free zinc ions [85, 86] . The nitrosylation of cysteines is readily reversible, typically through the activity of the S-nitrosoglutathione reductase or thioredoxin systems [87] . Subsequently, zinc ions released can bind to cysteine-rich regions in proteins such as PKCγ and Raf-1. However, if each cysteine were oxidized by NO, the CRDs of PKC and Raf-1 could not bind zinc ions and zincdependent regulation will fail. Most relevant, rather than protecting SH groups from oxidation, the strong binding of zinc to the sulfur in cysteine thiol groups increases the vulnerability of thiolates to oxidation. This critical feature means that zinc donors respond to mild physiological oxidation by releasing zinc ions, such as the oxidation produced by NO. By contrast, zinc-free cysteines in the acceptor proteins remain unaffected by this physiological concentration of NO and they are ready to capture free zinc ions [88] , such as the CRDs in the inactive PKC or Raf-1. The success of redox-active zinc/cysteine coordination environments, such as intracellular messengers, depends on their appropriate compartmentalization, and therefore, the elements in these systems must be in close proximity to facilitate the recovery of zinc for the next cycle [44] .
The concept of a biological redox switch or, more specifically, a redox zinc switch, involves motifs in peptides or proteins that utilize the redox chemistry of cysteine thiol groups to bind and release zinc ions [85, 89] . By controlling the availability of zinc, the cysteine ligand-based redox reactions are essential to modulate certain transient heterologous protein-protein interactions (quinary structure) [85] . The C1 regulatory domain of PKC is a zinc finger found in all PKC isozymes, and this domain is organized as a tandem C1A and C1B repeat in conventional PKCα/β/γ and novel PKCδ/ε/θ/η(L), coordinating the binding of four zinc equivalents, phorbol esters and DAG [90] . Far from cementing rigid structures, zinc acts as the linchpin that orchestrates dynamic changes in response to specific signals, providing an on/off switch for PKC activity. Thus, to convert PKC into an active enzyme, DAG (phorbol esters) releases two of the four zinc equivalents by reducing the affinity of histidine for zinc via the chain of hydrogen bonds [43, 44] . However, reactive oxygen species (ROS), that are moderate PKC activating agents, release all PKC zinc content [43, 91, 92] . Therefore, by dynamically regulating zinc content, both lipid second messengers and ROS affect PKC activity, switching the kinase between its unfolded active and folded inactive state, the latter binding more readily to the HINT1 protein at the MOR.
Plasticity of MOR-Induced Protein Assembly
In the absence of activation, the intracellular loops of the MOR bind different classes of heterotrimeric G proteins. The HINT1 homodimer binds to the MOR C-terminal sequence in a zinc-independent manner and it stabilizes the association of the C1 segment of the NMDAR NR1 subunits to this cytosolic region of the GPCR. The coupling of NR1 C1 segment to the HINT1 protein does not require zinc ions and it probably mimics that of Ca 2+ -CaM by diminishing the activity of the MOR-coupled NMDAR. However, the RGSZ2 protein that carries the zinc ions at its N-terminal CDR binds to the HINT1 protein in a manner independent of zinc. When the RGSZ2 PDZ binding motif that lies upstream of the RH domain binds nNOS PDZ domain the NO production is prevented (Figs. 6 and 7 ). Yet when morphine activates MORs, this protein assembly undergoes a series of changes that serve to activate the associated NMDAR to an extent proportional to that of the MOR [65] . As a result, the NMDAR diminishes the signaling strength of the MOR. While morphine is in the receptor environment, the positive MOR to NMDAR signals and the negative NMDAR to MOR signals diminish MOR signaling. After removal of the opioid agonist, MOR-mediated stimulation of the NMDAR function ceases, although if the strength of MOR signaling reached a given threshold, then MOR desensitization persists for hours and even days before the normal response to opioids is recovered [6, 7] .
Probably the first relevant event that initiates the development of opioid tolerance at MORs is the activation of HINT1-bound PKC (supplemental on line animation). The selectivity of many kinases, including PKC, is principally achieved by their translocation to the environment of their target proteins [93] . In the postsynapse, zinc-depleted inactive PKC is bound to A-kinase anchoring proteins (AKAPs) until it is released by Ca 2+ -CaM [94] . Therefore, in the absence of MOR activation the existing levels of Ca 2+ -CaM and of free zinc ions release inactive PKC to bind to the HINT1 homodimer (Fig. 8) . On morphine challenge, MOR-activated GαGTP subunits separate from Gβγ dimers, which can then regulate the PLCβ that is in close proximity to the receptor [25] . DAG unfolds PKC into its active conformation by interacting with the histidines of its regulatory zinc finger domain and releasing part of its zinc content [43, 91] . DAG also releases PKCγ from its inhibitory association with HINT1 by acting on their histidines and releasing the shared zinc ions. This action weakens the intermolecular bridges and disorders the surface of PKCγ involved in HINT1 binding, favoring the release of the active kinase [29, 39] . These concurrent processes position the inactive PKCγ in the MOR environment, where its activation is tightly regulated to prevent the unwanted spreading of its effects. Then active PKCγ can then act on a series of substrates involved in MOR desensitization.
Morphine-activated GαGTP subunits reach and regulate the corresponding cellular effectors, including RGSZ2-nNOS associated with the MOR-HINT1 complex. Thus, GαGTP binding to RGSZ2 exposes the HINT1-RGSZ2 interaction surface to active PKCγ which acting on the HINT1 protein, now promotes the release of the GαGTP-RGSZ2-nNOS complex [37] . On the other hand, morphine released Gβγ dimers stimulate the PI3K/Akt pathway to phosphorylate and activate nNOS [49, 65, 95] . The increased NO in the MOR compartment releases free zinc ions from endogenous stores [96] , the zinc finger of RGSZ2 included [29] . At this stage, the action of NO on the redox transducer, the RGSZ2 protein, increases the Fig. 6 The HINT-1 homodimer bridges the MOR C terminus and the RGSZ2 protein. The HINT1 homodimer physically interacts with the MOR C terminus and with the RGSZ2 proteins in a zinc-independent manner [29, 37, 42] Fig . 7 Competitive binding of RGSZ2 and NR1 C1 for the HINT1 homodimer. The association between the RGSZ2 PDZ binding motif upstream of the RH domain and nNOS PDZ domain does not require of zinc ions [7, 49] . The HINT1 homodimer binds to the MOR Cterminal sequence in a zinc-independent manner and it stabilizes the binding of the C1 segment of the NMDAR NR1 subunits to this cytosolic region of the GPCR. The coupling of NR1 C1 to the HINT1 protein does not require zinc ions and it probably mimics that of Ca 2+ -CaM diminishing the activity of the MOR-coupled NMDAR [73] availability of free zinc ions to foment the binding of the redox sensor protein, PKCγ, to the HINT1 protein where DAG can promote its activation and release from HINT1 inhibition (Fig. 8) .
The GαGTP subunits that reach the RGSZ2-nNOS complex are converted there into GαGDP by GαGTPase, where they are rescued by Gβγ dimers to reform the trimeric G protein under the regulation of the MOR. In this cycle, morphine tolerance does not develop. Accordingly, the association RGSZ2 proteins-Gα subunits promoted by doses of morphine that produce little or no tolerance disappears as analgesia fades, whereas the activation of the NMDAR/CaMKII pathway is moderated [22, 23] . However, if the effects of morphine reach a critical level, some Gα subunits remain attached to the RGSZ2 proteins, process that is facilitated by the enhanced MOR-mediated NMDAR activity. In this compartment, inactive Src is found bound at PSD95 proteins [97, 98] , and the active PKCγ fomented by morphine via the production of DAG at PLCβ activates Src. These kinases act on the NR1 C1 and NR2 subunits, respectively, augmenting Ca 2+ permeation at NMDARs [39, 72] . In such circumstances, the binding of Gα-RGSZ2 can be stabilized by third-party proteins, such as RGS9 and 14-3-3, followed by phosphorylation by PKC [6, 19, 22, 24, 25] . The 14-3-3-RGS9-Gα-RGSZ2 complexes persist for hours after morphine analgesia disappears, and this reduction in MOR-regulated G proteins (Gα retained by RGS proteins) favors the phosphorylation that uncouples morphine-activated MORs through PKC and/or CaMKII activity [6, 7, 99] , and opioid tolerance develops (Fig. 9) .
Besides PKC, Raf-1 is also recruited to the MOR-HINT1 complex in a zinc-dependent fashion (Fig. 8) . The CRDs of both Raf-1 and PKCγ bind simultaneously to the HINT1 homodimer, enabling active PKCγ to enhance Raf-1 function and intensify MEK/ERK1/2 activation. Thus, the MOR via HINT1 protein facilitates the cross-talk of two NO-and zinc-regulated signal transduction pathways implicated in the potentiation of NMDAR signals, PKC/Src and Raf-1/ERK1/2 that are consequently involved in the negative control of the effects of morphine [100, 101] .
An issue of particular interest is the desensitization of MORs that persists long after the opioid has been removed from the receptor environment, and while the NMDAR/CaMKII pathway shows weak activity. This situation of long-term opioid tolerance is mostly due to the permanent activity of PKC that maintains MOR-regulated Gα subunits sequestered at RGSZ2/RGS9 proteins, and if necessary, which can rapidly recruit the negative influence of NMDARs on MOR signaling. This activity of PKC preserves the phosphorylation of the NR1 C1 segment that separates the NMDAR from the inhibitory influence of MOR-HINT1 complex, and it also prevents the inhibitory binding of Ca 2+ -CaM. Therefore, morphine challenge can Fig. 8 Simultaneous binding of PKC and Raf-1 to the HINT1 homodimer. Whilst the binding of HINT1 to the MOR C terminus does not require zinc ions, that of PKCγ to HINT1 depends on the availability of these metal ions [29, 39, 42] . This zinc-mediated binding of PKCγ to the HINT1 protein at the MOR C terminus stabilizes the kinase in its inactive form [29, 39] . NO-released endogenous zinc ions also recruit the Ras/Raf-1/ERK1/2 cassette to the HINT1 protein [42] . As observed for conventional PKCs, the zinc ions bridge the association of the Raf-1 CRD with HINT1 at the MOR C terminus produce a rapid and intense response of NMDARs to quickly dampen MOR signaling, thereby maintaining opioid tolerance. The critical issue is the mechanism that keeps PKC active if the MOR does not regulate the production of NO or DAG. This permanent activation appears to be mediated by the action of ROS on the regulatory domain of DAG-activated PKC. This kinase can be activated by ROS, albeit not to the level of activation induced by cofactors such as DAG and calcium but rather, ROS fix the kinase in a persistent, autonomously active form [92, 102] . Significantly, NADPH oxidase/ROS production and the sustained activation of PKCγ triggered by opioids are essential to develop and maintain NMDAR-mediated tolerance to the analgesic effects of morphine [24, 103] . The sequence of events initiates with the excessive activation of the MOR that, with the aid of the NMDAR, recruits PKCγ activity sufficient strong as to reach and phosphorylate the NADPH oxidase subunits and enhance ROS production [104] . The subsequent binding of ROS to the PKC regulatory domain removes DAG-resistant zinc and fixes the kinase in its active state [92] , thereby maintaining the long-term desensitization of MORs. On inhibition of PKC, of nNOS, or NMDAR antagonism, morphine analgesic tolerance is rescued to normal function. This functional parameter correlates with the re-association of MOR-NR1 complexes, the disruption of Gα-RGSZ2 sequestering, MOR dephosphorylation and the recovery of the regulated transduction [7] .
Summary and Perspectives
In nervous tissue, the NMDAR negatively regulates MOR signaling through redox processes and zinc metabolism. Analgesic tolerance is maintained by regulatory processes triggered by NMDARs that prevent the MOR from recovering normal transduction. The potentiation of the NMDAR is directly related to MOR function and thus, the signals of the NMDAR interweave with those of the MOR until NMDAR activity effectively diminishes that of the MOR or if promotes PKC-mediated long-term desensitization. This regulatory cross-talk prevents over-activation of the Fig. 9 MOR-induced protein assemblies in the tolerance. a The crosstalk between the MOR and the NMDAR mediates both positive (MOR signaling enhances NMDAR function) and negative effects (NMDAR activity attenuates the strength of the MOR signaling). The activation of CaMKII by NMDAR directly or indirectly promotes the inactivating phosphorylation of the MOR. b Morphine stimulates the separation of G proteins into Gβγ dimers and active Gα-GTP subunits. Some of the Gα-GTP subunits bind RGSZ2 while Gβγ dimers regulate PLCβ. DAG separates inactive PKCγ from its binding to the HINT1 protein, and activates the kinase. c (1) MOR-activated PKCγ increases the function of the associated NMDAR. PKCγ phosphorylates the C1 segment of NR1 subunits, and also promotes the activation of Src which in turn acts on specific residues at NR2 subunits. The action of both kinases on NMDARs enhances glutamate-triggered calcium influxes. (2) PKCγ regulates Raf-1. PKCγ enhances the activity of Raf-1 to increase that of MOR-associated ERK1/2 pathway. The activated ERK1/2 augments AMPA activity, contributing to the enhancement of NMDAR function and promoting synaptic LTP. (3) PKCγ stabilizes the sequestering of Gα subunits by the RGSZ2/RGS9 complex. The action of PKCγ at the RGS9 RH domain promotes the subsequent binding of 14-3-3 proteins to stabilize the RGSZ2-Gα-RGS9 complex. (4) Long-term consolidation of MOR desensitization. The tolerance that develops after a single dose of morphine last typically 3 to 4 days, long after morphine has been removed from the MOR environment. The action of PKCγ on subunits of the NOX/ NADPH complex promotes ROS production. These strong oxidizers remove DAG-resistant zinc from PKCγ regulatory domain and fix the kinase in a permanent active state until it is probably metabolized. This process is necessary to sustain MOR tolerance after morphine is cleared from the receptor NMDAR and the reduction in MOR signaling provokes a parallel decrease in NMDAR signaling.
It was recently reported that HINT1, and several of the MOR signaling assembles, are also associated with other GPCRs [29] . Thus, redox signaling may represent a process common to the most abundant subfamily of cell surface receptors, mobilizing zinc ions from intracellular stores to successfully integrate their signals into adaptive neuronal processes. This finding opens the way to study the relationship between GPCR regulation by redox processes and zinc metabolism in certain pathological situations involving neural dysfunctions.
